预约演示

更新于：2026-02-27

Latanoprost

拉坦前列素

更新于：2026-02-27

概要

基本信息

药物类型

小分子化药

别名

L-PPDS、AL-37807、AR-202

+ [29]

靶点

PTGFR

作用方式

激动剂

作用机制

PTGFR激动剂(前列腺素FP受体激动剂)

治疗领域

眼部疾病

在研适应症

眼部疾病青光眼开角型青光眼+ [2]

非在研适应症

角膜疾病虹膜色素剥脱综合征闭角型青光眼+ [2]

原研机构

在研机构

+ [7]

非在研机构

Sun Pharmaceutical Industries Ltd.

Santen Pharmaceutical Co., Ltd.Santen SAS

+ [2]

权益机构

深圳市康哲药业有限公司

EyePoint Plc

欧康维视生物医药（上海）有限公司

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1996-06-05),

开角型青光眼高眼压症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H40O5

InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N

CAS号130209-82-4

关联

210

项与拉坦前列素相关的临床试验

NCT07425535

/ Not yet recruiting早期临床1期IIT

Optic Nerve Head Strain in Non-glaucoma Subjects

Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.

开始日期2026-03-01

申办/合作机构

The Johns Hopkins University

[+1]

PACTR202512840605479

/ Recruiting临床3期IIT

Selective laser trabeculoplasty versus latanoprost as first line treatments for primary open angle glaucoma and ocular hypertension: A comparative analysis

开始日期2025-12-15

申办/合作机构-

NCT07016113

/ Not yet recruiting临床2期

Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children

Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.

开始日期2025-07-01

申办/合作机构

Universitas Padjadjaran

100 项与拉坦前列素相关的临床结果

登录后查看更多信息

100 项与拉坦前列素相关的转化医学

登录后查看更多信息

100 项与拉坦前列素相关的专利（医药）

登录后查看更多信息

2,136

项与拉坦前列素相关的文献（医药）

2026-03-01·JOURNAL FRANCAIS D OPHTALMOLOGIE

Investigation of the effect of latanoprostene bunod and latanoprost on peripapillary optical coherence tomography angiography

Article

作者: Doğan, L ; Özer, Ö ; Baysal, Z ; Biçer, G Yildirim

PURPOSE:

To evaluate the effects of once daily latanoprostene bunod (LBN) and latanoprost (LP) on peripapillary optical coherence tomography angiography (OCTA) measurements in open angle glaucoma patients and to compare the outcomes.

METHODS:

In this prospective, randomized clinical trial, Inclusion criteria were age 40years and older, open angle on gonioscopic examination, and intraocular pressure (IOP) ≥21mmHg with Goldmann applanation tonometry. All participants were divided into two groups by computer-based randomization: Vyzulta® (0.024% LBN, group 1) and Xalatan® (0.005% LP, group 2). Peripapillary OCTA imaging was performed before and one month into treatment.

RESULTS:

The IOP level measured in the first month of treatment was significantly lower in group 1 compared to group 2 (P<0.001). The mean IOP change (ΔIOP) was -34.4% in group 1 and -26.6% in group 2 (P<0.001). In the post-treatment period, the vessel density (VD) levels in the temporal quadrant (P=0.028) of the superficial slab, the inferior (P=0.029), nasal (P=0.005) and temporal quadrants (P=0.007) of the deep slab, and the inferior (P=0.014) and nasal (P=0.038) quadrants of the choriocapillaris slab were significantly higher in group 1 compared to group 2.

CONCLUSIONS:

In conclusion, LBN administered once a day increased VD in peripapillary OCTA. LP had no effect on VD. Future studies should be aimed at determining whether this effect of LBN is NO induced or due to higher IOP reduction.

2026-03-01·VETERINARY OPHTHALMOLOGY

Owner Obtained Intraocular Pressure Measurements in Canine Primary Angle Closure Glaucoma: A Pilot Study in 14 Dogs

Article

作者: Westermeyer, Hans D. ; Salmon, Jacklyn H.

ABSTRACT:

Purpose:

To explore the clinical value of intraocular pressure (IOP) measurements obtained by owners in dogs predisposed to primary angle closure glaucoma (PACG).

Materials and Methods:

Owners of 14 dogs with eyes predisposed to developing PACG obtained IOP measurements with a TonoVet Plus from the time of diagnosis of PACG until they developed clinical PACG or were lost to follow up.

Results:

Owners measured IOP values in 14 dogs. In nine dogs, IOP was measured until they developed overt glaucoma with marked IOP elevations. Four dogs were lost to follow‐up, and IOP continues to be monitored in one dog. In seven of the nine dogs that developed overt glaucoma, onset of glaucoma was associated with a sudden rise in IOP > 50 mmHg that was not preceded by an obvious gradual rise in average IOP readings or prior smaller rises in IOP. Dogs that were treated with latanoprost following the onset of overt glaucoma continued to have sporadic rises in IOP.

Conclusion:

Owner obtained, at home IOP measurements can provide information that may be useful in the management of canine PACG.

2026-02-01·OTOLOGY & NEUROTOLOGY

Latanoprost for Treatment of Ménière Disease: A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Intratympanic Management for Symptom Control

Article

作者: Engmér Berglin, Cecilia ; Lindell, Ellen ; Karlberg, Berglin Mikael ; Dahlin Redfors, Ylva ; Tomanovic, Tatjana

Objective::

A previous placebo-controlled crossover study of intratympanic latanoprost—a drug commonly used for glaucoma treatment—showed positive effects on hearing, tinnitus, and vertigo in patients with long-standing Ménière disease (MD). We aimed to test the safety and efficacy of intratympanic treatment with latanoprost 0.0005% versus placebo in patients with active MD concerning speech discrimination in noise, hearing, tinnitus, and vertigo.

Study design::

A prospective, randomized, double-blind, placebo-controlled study over 3 months in patients with active stage II to III MD.

Setting::

Twelve otolaryngology referral centers across Sweden.

Intervention::

Patients were allocated to intratympanic injection of latanoprost 0.0005% administered as a single injection on day 1, or 3 injections over 3 consecutive days, or placebo administered as a single injection or 3 injections over 3 consecutive days.

Main outcome measures::

The primary outcome was change in speech discrimination in noise, assessed using phonetically balanced monosyllabic Swedish words (PB S/N+4dB), from baseline (day 1) to day 14. Secondary outcomes were change in pure tone average measured at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz, tinnitus according to the Tinnitus Handicap Inventory (THI) score and vertigo measured at 2, 4, 6, and 8 weeks after the first injection. Hearing, tinnitus, and vertigo were also assessed according to a Likert scale scored from 0 to 10. Days with vertigo attacks lasting ≥20 minutes were registered twice a week by patients. LS means were compared for each outcome measure.

Results::

When comparing latanoprost (1 or 3 injections) with placebo (1 or 3 injections), no statistically significant difference was seen for the change in speech discrimination in noise from baseline to day 14, 0.4 (95% CI: −4.5; 5.3), P =0.88. None of the secondary efficacy measures showed a statistically significant difference between latanoprost and placebo. Latanoprost treatment was well tolerated.

Conclusions::

In this placebo-controlled study, latanoprost was not more effective than placebo in the treatment of MD and did not improve speech discrimination in noise, hearing, and tinnitus or vertigo symptoms.

160

项与拉坦前列素相关的新闻（医药）

2026-02-24

·BioSpace

Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting

Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Pro the 2026 American Glaucoma Society Annual Meeting February 24, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that positive data from the NCX 470 Phase 3 studies were highlighted in 2 podium presentations and a poster at the 2026 American Glaucoma Society (AGS) Annual Meeting (February 19 to February 22), one of the key scientific events in vision research. Data presented at AGS show that NCX 470, a novel, fast acting molecule, demonstrated best-in-class intraocular pressure (IOP) lowering efficacy of up to 10mmHg from baseline which has met the efficacy requirements for a New Drug Application in the U.S. and China. “ Presentation of our NCX 470 Phase 3 data at the prominent American Glaucoma Society meeting validates the importance of our development program in bringing an innovative intraocular pressure lowering drug to patients. Approximately 40% of glaucoma patients do not achieve their target intraocular pressure on existing monotherapies, therefore physicians need new and different effective treatment options, and we believe that NCX 470 could meet that need, ” said Doug Hubatsch, Chief Scientific Officer of Nicox. “ These data further reinforce results we have previously announced demonstrating the robust intraocular pressure lowering effect and favourable safety pro NCX 470. Furthermore, our clinical data presented validate the dual mechanism of intraocular pressure lowering through the trabecular meshwork and uveoscleral pathways that had previously been shown in animal models. Importantly, pre-planned analysis of the NCX 470 Phase 3 data demonstrates additional differentiation in intraocular pressure reduction; and preclinical data, which have already been reported, suggest potential benefits in retinal protection. ” Details of the AGS presentations Podium presentation : “A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial” presented by Dr. S. Asrani, Duke University Medical Center, Durham, NC The Denali phase 3 clinical trial met its primary endpoint of demonstrating non-inferiority of NCX 470 0.1% to latanoprost 0.005% at every time point. NCX 470 demonstrated fast, powerful, and consistent intraocular pressure (IOP) reduction of up to 10mmHg that was statistically superior to latanoprost at 3 of 6 time points. NCX 470 was safe and well tolerated with a low discontinuation rate. Podium presentation : “Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial” presented by Dr. A. Sit, Mayo Clinic, Rochester, Minnesota Aqueous humor dynamics were measured in healthy adults without glaucoma. Subjects were randomized to receive either artificial tears or NCX 470 0.1% dosed once daily. NCX 470 significantly lowered IOP by a dual mechanism of action , increasing both the outflow facility and uveoscleral outflow. Poster: “Outcomes in the United States Subgroup of the Denali Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension” presented by Dr. J. Bacharach, North Bay Eye Associates, Inc., Petaluma, CA In the U.S. subgroup of the Phase 3 Denali trial, NCX 470 0.1% demonstrated robust IOP lowering in patients with open-angle glaucoma or ocular hypertension. NCX 470 met the pre-specified non-inferiority criteria compared with latanoprost 0.005% and achieved statistically greater IOP reductions at 3 of 6 evaluated timepoints. NCX 470 was safe and well tolerated, with no treatment-related serious adverse events and low, similar discontinuation rates between treatment groups. The presentations and the poster are available on Nicox’s website in the section Publications . About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2024 ” and in section 4 of the “ Rapport semestriel 2025” which are available on Nicox’s website ( ). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 Attachment EN_AGS 2026 posters presented_FINAL

临床结果临床3期

2026-02-11

·药通社

小众品种，突然火爆！

在药物研发史上，因为药物出现的副作用阴差阳错转变出全新适应症的产品非常多，最知名的就是“伟哥”西地那非。西地那非原本是治疗心绞痛的药物，但由于临床疗效不佳，副作用过多，辉瑞被迫停止研究，转折也由此开始。在进行实验回收的时候，辉瑞发现很多男性患者并不愿意交出手里的剩余药物，并且还有偷偷藏药的现象。追查之后才了解到，西地那非虽然不能明显缓解心绞痛，但它的“副作用”则可以大幅改善受试者的ED问题，全球首款也最成功的治疗ED药物便就此诞生。自此后因副作用而诞生新适应症的药物比比皆是，2025年国内火爆的就有一款，贝美前列素涂剂。贝美前列素涂剂也是从副作用中诞生的产品，“伟哥”针对男性需求，而贝美前列素涂剂聚焦的则是女性市场，因其可以增长睫毛。贝美前列素涂剂从2025年起，一年就得了6张临床批件，可见国内企业也注意到了这个与“美容”相关的小众品种。图源：摩熵医药贝美前列素原是一款滴眼液，用于治疗青光眼，由全球知名眼药公司艾伯维旗下公司艾尔建研发，滴眼液名LUMIGAN，2001年在美国上市。作为一款滴眼液，贝美前列素滴眼液在全球的销售额可以说相当不错了，艾伯维年报公布，LUMIGAN在2024年销售额达4.29亿美元。 2005年，艾尔建就将滴眼液引入了国内，然而在国内青光眼治疗药物有诸多产品，7大类多款品种有售，目前国内治疗青光眼销量最佳是宇宙大厂辉瑞的拉坦前列素滴眼液，且贝美前列素滴眼液不进医保，故而国内一年销售额在两千万左右，市场并不大，原研占销售大头。贝美前列素滴眼液国内共有原研艾尔建、湖北远大、山东威智和兆科眼科四家有产品上市，兴齐眼药和津药和平等5家企业提交了上市申请，属于中规中矩的竞争格局。而从2024年底开始，另一款与贝美前列素相关的外用涂剂开始火爆，正如开头所说，一年内批出6张临床批件，另有2家已申请了临床。贝美前列素涂剂和西地那非一样，也是基于副作用研发出来的品种。艾尔建发现，贝美前列素滴眼液接触到眼睑会使睫毛增长，眼睑变黑，这本是副作用，但艾尔建从中获取到了灵感，进而研发了涂剂。外用贝美前列素涂剂名LATISSE，2008年上市，适应症是睫毛稀少症。 LATISSE是FDA批准的首个促进睫毛更长、更浓密的药物，上市时引发了轰动。受药品管理，涂一涂可增长睫毛，这一系列宣传足以令市场疯狂。国内这两年也是突然注意到了这个颇有卖点的小众品种，纷纷入局。然而艾尔建这款涂剂虽有噱头，但能否复制“伟哥”商业化的成功，需要打个问号。说起来美容是个非常广阔的市场，不少女性愿意为美丽买单，但是从贝美前列素涂剂的销售数据看，这款增长睫毛的外用涂剂，销售情况并不好。 LATISSE上市太早，前期数据不可考，到2015年，艾伯维在年报首次提及这款涂剂，全球销售额7300万美元，最后提到这款产品的销售情况是在2017年销售额6470万美元，后续年报再未单独提及销售数据。从目前看来，艾尔建并未打算将贝美前列素涂剂引入国内，倒是在香港和台湾有过上市，但目前已退市。虽然该涂剂暂未正式进入中国，但国家药监局已将其纳入参比制剂目录。图源：摩熵医药目前贝美前列素涂剂获得临床批件的企业已达6家，但这类适应症的临床试验该如何进行，国内暂无指导原则，目前也暂无任何企业有临床进度。一个品种能否成为爆品不止需要看研发，还要看商业化情况，这个品未来商业化情况不好预测，国内美容需求庞大，未必不能成为爆品。 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

2026-02-08

·信狐药迅

两个国产创新药新适应症获批上市：艾力斯伏美替尼和科伦博泰芦康沙妥珠单抗| 新获批(2.2-2.8）

每周药品注册获批数据，分门别类呈现，一目了然。(2.2-2.8）新药上市申请药品名称企业注册分类受理号甲磺酸伏美替尼片上海艾力斯医药科技股份有限公司 2.4 CXHS2500084 盐酸安罗替尼胶囊正大天晴药业集团股份有限公司 2.4 CXHS2500035 注射用芦康沙妥珠单抗四川科伦博泰生物医药股份有限公司 2.2 CXSS2500052 新药临床申请药品名称企业注册分类受理号 ICP-538片北京诺诚健华医药科技有限公司 1 CXHL2600035 ICP-538片北京诺诚健华医药科技有限公司 1 CXHL2600034 ICP-538片北京诺诚健华医药科技有限公司 1 CXHL2600033 ABP-745片杭州新元素药业股份有限公司 1 CXHL2501525 LDR2515注射液成都先衍生物技术有限公司 1 CXHL2501532 APG-3288片苏州亚盛药业有限公司 1 CXHL2501514 APG-3288片苏州亚盛药业有限公司 1 CXHL2501513 SY-9453胶囊首药控股(北京)股份有限公司 1 CXHL2501324 SY-9453胶囊首药控股(北京)股份有限公司 1 CXHL2501323 XW014片杭州先为达生物科技股份有限公司 1 CXHL2501322 XW014片杭州先为达生物科技股份有限公司 1 CXHL2501321 ANS014004片北京鞍石生物科技股份有限公司 1 CXHL2501320 ANS014004片北京鞍石生物科技股份有限公司 1 CXHL2501319 XTYW007片西安新通药物研究股份有限公司 1 CXHL2501327 XTYW007片西安新通药物研究股份有限公司 1 CXHL2501326 XTYW007片西安新通药物研究股份有限公司 1 CXHL2501328 注射用SJ001 上海施江生物科技有限公司 1 CXHL2501309 BEBT-701注射液广州必贝特医药股份有限公司 1 CXHL2501308 UBT251注射液联邦生物科技(珠海横琴)有限公司 1 CXHL2501306 CMS-D017胶囊深圳市康哲生物科技有限公司 1 CXHL2501314 CMS-D017胶囊深圳市康哲生物科技有限公司 1 CXHL2501313 RG002C0106注射液北京炫景瑞医药科技有限公司 1 CXHL2501310 HS-10390片常州恒邦药业有限公司 1 CXHL2501305 塞拉维诺片中国科学院上海药物研究所 1 CXHL2501300 塞拉维诺片中国科学院上海药物研究所 1 CXHL2501299 TJ0113胶囊杭州天玑济世生物科技有限公司 1 CXHL2501298 ABSK-011胶囊上海和誉生物医药科技有限公司 1 CXHL2501290 ABSK-011胶囊上海和誉生物医药科技有限公司 1 CXHL2501291 ABSK-011胶囊上海和誉生物医药科技有限公司 1 CXHL2501292 DP22001口服乳中国科学院上海药物研究所 2.2 CXHL2501307 SBK014干混悬剂成都施贝康生物医药科技有限公司 2.2 CXHL2501296 带状疱疹mRNA疫苗安徽智飞龙科马生物制药有限公司 1.2 CXSL2500961 重组带状疱疹ZFA01佐剂疫苗(CHO细胞) 安徽智飞龙科马生物制药有限公司 1.3 CXSL2500978 B群脑膜炎球菌OMV疫苗上海羽冠生物技术有限公司 2.2 CXSL2500969 B群脑膜炎球菌OMV疫苗上海羽冠生物技术有限公司 2.2 CXSL2500968 B群脑膜炎球菌OMV疫苗上海羽冠生物技术有限公司 2.2 CXSL2500967 冻干水痘灭活疫苗安徽智飞龙科马生物制药有限公司 2.2 CXSL2500962 冻干人用狂犬病疫苗(人二倍体细胞) 浙江普康生物技术股份有限公司 2.5 CXSL2500972 注射用GenSci136 长春金赛药业有限责任公司 1 CXSL2600033 注射用HMPL-A580 和记黄埔医药(上海)有限公司 1 CXSL2600011 注射用经应激诱导的间充质干细胞衍生物达尔文起点(湖北)生物制药有限责任公司 1 CXSL2501153 注射用SSS50 沈阳三生制药有限责任公司 1 CXSL2501038 HB0056注射液上海华奥泰生物药业股份有限公司 1 CXSL2501039 VERT-002注射液皮尔法伯(上海)医疗科技有限公司 1 CXSL2501031 注射用GQ1001冻干粉针剂启德医药科技(苏州)有限公司 1 CXSL2501029 注射用SSS57 沈阳三生制药有限责任公司 1 CXSL2501027 AK139注射液中山康方生物医药有限公司 1 CXSL2501026 AK139注射液中山康方生物医药有限公司 1 CXSL2501024 AK139注射液中山康方生物医药有限公司 1 CXSL2501023 注射用SSS57 沈阳三生制药有限责任公司 1 CXSL2501019 HL08 华兰生物工程股份有限公司 1 CXSL2501017 DR10624注射液浙江道尔生物科技有限公司 1 CXSL2501013 ESG206注射液上海诗健生物科技有限公司 1 CXSL2501011 注射用HBT-708 沈阳三生制药有限责任公司 1 CXSL2501007 注射用HBT-708 沈阳三生制药有限责任公司 1 CXSL2501006 IBI3013 信达生物制药(苏州)有限公司 1 CXSL2501010 IBI3013 信达生物制药(苏州)有限公司 1 CXSL2501009 注射用ASKG915 江苏奥赛康生物医药有限公司 1 CXSL2501005 SENL103自体T细胞注射液河北森朗生物科技有限公司 1 CXSL2500958 人脐带间充质干细胞注射液杭州易文赛生物技术有限公司 1 CXSL2500951 卡度尼利单抗注射液(皮下注射) 康方药业有限公司 2.1 CXSL2501034 泰它西普注射液荣昌生物制药(烟台)股份有限公司 2.1;2.2 CXSL2501028 注射用MK-2870 默沙东研发(中国)有限公司 2.2 CXSL2501037 注射用MK-2870 默沙东研发(中国)有限公司 2.2 CXSL2501036 注射用MK-2870 默沙东研发(中国)有限公司 2.2 CXSL2501016 阿得贝利单抗注射液上海盛迪医药有限公司 2.2 CXSL2500979 注射用重组A型肉毒毒素河北封章生物科技有限公司 2.4 CXSL2501012 仿制药申请药品名称企业注册分类受理号比拉斯汀口服溶液南京黄龙生物科技有限公司 3 CYHS2502060 盐酸异丙肾上腺素注射液江苏迪赛诺制药有限公司 3 CYHS2502023 盐酸异丙肾上腺素注射液江苏迪赛诺制药有限公司 3 CYHS2502022 比拉斯汀口服溶液嘉亨(珠海横琴)医药科技有限公司 3 CYHS2502018 对乙酰氨基酚布洛芬片南京海纳医药科技股份有限公司 3 CYHS2500835 甲氨蝶呤片海南卓科制药有限公司 3 CYHS2500619 门冬氨酸钾镁注射液海南慧通生物医药科技有限公司 3 CYHS2500049 钠钾镁钙注射用浓溶液成都瑞尔医药科技有限公司 3 CYHS2402996 盐酸布比卡因注射液石家庄凯达生物工程有限公司 3 CYHS2403026 舒林酸片沐源(安徽)药业有限公司 3 CYHS2402934 吡拉西坦注射液西藏海金药业有限公司 3 CYHS2402512 吡拉西坦注射液西藏海金药业有限公司 3 CYHS2402511 盐酸艾司氯胺酮注射液成都倍特药业股份有限公司 3 CYHS2402446 法莫替丁注射液成都康泰源医药科技有限责任公司 3 CYHS2402403 法莫替丁注射液成都康泰源医药科技有限责任公司 3 CYHS2402402 注射用盐酸罗沙替丁醋酸酯沈阳新马药业有限公司 3 CYHS2402066 复方聚乙二醇(3350)电解质口服溶液广西维威制药有限公司 3 CYHS2402002 维生素B6注射液海南皇隆制药股份有限公司 3 CYHS2401955 酒石酸美托洛尔注射液北京远方通达医药技术有限公司 3 CYHS2401933 盐酸溴己新口服溶液福元药业有限公司 3 CYHS2401932 法莫替丁注射液海南未见药业有限公司 3 CYHS2401455 盐酸多西环素片浙江赛默制药有限公司 3 CYHS2401422 盐酸多西环素片浙江赛默制药有限公司 3 CYHS2401421 盐酸氨溴索滴剂南京海纳制药有限公司 3 CYHS2401318 米诺地尔搽剂浙江浙北药业有限公司 3 CYHS2401225 米诺地尔搽剂浙江浙北药业有限公司 3 CYHS2401224 米诺地尔搽剂山东华铂凯盛生物科技有限公司 3 CYHS2400977 米诺地尔搽剂山东华铂凯盛生物科技有限公司 3 CYHS2400976 恩格列净二甲双胍缓释片乐普药业股份有限公司 3 CYHS2400624 恩格列净二甲双胍缓释片乐普药业股份有限公司 3 CYHS2400623 恩格列净二甲双胍缓释片乐普药业股份有限公司 3 CYHS2400622 小儿复方氨基酸注射液(19AA-I) 天津金耀药业有限公司 3 CYHS2302761 普瑞巴林口服溶液上海美优制药有限公司 3 CYHS2300005国;CYHS2300005 硫酸氨基葡萄糖胶囊江西铜鼓仁和制药有限公司 4 CYHS2504334 艾拉莫德片宜昌东阳光长江药业股份有限公司 4 CYHS2503152 聚乙烯醇滴眼液四川好医生攀西药业有限责任公司 4 CYHS2502634 碳酸镧咀嚼片康臣药业(内蒙古)有限责任公司 4 CYHS2501023 碳酸镧咀嚼片康臣药业(内蒙古)有限责任公司 4 CYHS2501022 硫酸氨基葡萄糖胶囊四川新斯顿制药股份有限公司 4 CYHS2404083 硫酸氨基葡萄糖胶囊苏州第四制药厂有限公司 4 CYHS2403877 聚乙烯醇滴眼液苏州乐珠制药有限公司 4 CYHS2403847 美阿沙坦钾片江西施美药业股份有限公司 4 CYHS2403818 美阿沙坦钾片江西施美药业股份有限公司 4 CYHS2403817 卡格列净片浙江诺得药业有限公司 4 CYHS2403626 沙库巴曲缬沙坦钠片湖南威特制药股份有限公司 4 CYHS2403620 沙库巴曲缬沙坦钠片湖南威特制药股份有限公司 4 CYHS2403619 阿法骨化醇软胶囊大连美创药业有限公司 4 CYHS2403490 阿法骨化醇软胶囊大连美创药业有限公司 4 CYHS2403489 头孢丙烯片华北制药河北华民药业有限责任公司 4 CYHS2403463 枸橼酸西地那非口腔崩解片四川省通园制药集团有限公司 4 CYHS2403279 硫酸艾沙康唑胶囊江西艾施特制药有限公司 4 CYHS2403240 达格列净片任曦医药科技河北有限公司 4 CYHS2403161 培哚普利氨氯地平片(III) 桂林华信制药有限公司 4 CYHS2403160 地夸磷索钠滴眼液江苏万高药业股份有限公司 4 CYHS2403146 盐酸氨溴索口服溶液北京四环科宝制药股份有限公司 4 CYHS2403121 盐酸氨溴索口服溶液北京四环科宝制药股份有限公司 4 CYHS2403120 盐酸氨溴索口服溶液北京四环科宝制药股份有限公司 4 CYHS2403119 盐酸氨溴索口服溶液北京四环科宝制药股份有限公司 4 CYHS2403118 坎地沙坦酯片珠海润都制药股份有限公司 4 CYHS2403102 奥美沙坦酯片修正药业集团长春高新制药有限公司 4 CYHS2402945 玻璃酸钠滴眼液石家庄凯达生物工程有限公司 4 CYHS2402932 玻璃酸钠滴眼液石家庄凯达生物工程有限公司 4 CYHS2402931 小儿法罗培南钠颗粒湖南普道医药技术有限公司 4 CYHS2402888 甲钴胺片湖北广济药业股份有限公司 4 CYHS2402791 复方氨基酸注射液(18AA-VII) 武汉久安药物研究院有限公司 4 CYHS2402708 硫酸氨基葡萄糖胶囊山东新华制药股份有限公司 4 CYHS2402615 莫匹罗星软膏山东如至生物医药科技有限公司 4 CYHS2402324 注射用醋酸西曲瑞克南京海融制药有限公司 4 CYHS2402278 非布司他片温岭市创新生物医药科技股份有限公司 4 CYHS2402180 非布司他片温岭市创新生物医药科技股份有限公司 4 CYHS2402179 乳果糖口服溶液江苏广承药业有限公司 4 CYHS2401706 乳果糖口服溶液重庆和平制药有限公司 4 CYHS2401612 拉坦前列素滴眼液广州仁恒医药科技股份有限公司 4 CYHS2401577 富马酸伏诺拉生片天方药业有限公司 4 CYHS2401374 富马酸伏诺拉生片天方药业有限公司 4 CYHS2401373 盐酸氟西汀分散片山东达因海洋生物制药股份有限公司 4 CYHS2401339 依折麦布阿托伐他汀钙片南京海纳制药有限公司 4 CYHS2401279 依折麦布阿托伐他汀钙片南京海纳制药有限公司 4 CYHS2401278 硫辛酸注射液北京双鹭药业股份有限公司 4 CYHS2401186 盐酸尼卡地平注射液海南爱科制药有限公司 4 CYHS2401045 帕妥珠单抗注射液杭州博之锐生物制药有限公司 3.3 CXSS2400116 注射用甲磺酸萘莫司他天津红日药业股份有限公司 3 CYHL2500211 盐酸西替利嗪滴眼液南京海纳制药有限公司 3 CYHL2500210 非那雄胺喷雾剂福元药业有限公司 4 CYHL2500207 进口申请药品名称企业注册分类受理号达罗他胺片 Bayer HealthCare Pharmaceuticals Inc. 2.4 JXHS2500001 伊曲莫德片 EVEREST MEDICINES (SINGAPORE) PTE. LTD. 5.1 JXHS2400112 THR1442片 TheracosBio, LLC 5.1 JXHS2400002 达雷妥尤单抗注射液(皮下注射) Janssen-Cilag International NV 3.1 JXSS2500061 司库奇尤单抗注射液 Novartis Pharma Schweiz AG 3.1 JXSS2500054 帕博利珠单抗注射液 Merck Sharp & Dohme LLC 3.1 JXSS2500051 注射用重组人促卵泡黄体激素α Merck Europe B.V. 3.1 JXSS2300059 注射用塞替派 Esteve Pharmaceuticals GmbH 5.2 JYHS2400035 他克莫司胶囊 Alkem Laboratories Limited 5.2 JYHS2101030国;JYHS2101030 他克莫司胶囊 Alkem Laboratories Limited 5.2 JYHS2101029国;JYHS2101029 他克莫司胶囊 Alkem Laboratories Limited 5.2 JYHS2101031国;JYHS2101031 AMG 436 Amgen Inc. 1 JXHL2500397 AMG 436 Amgen Inc. 1 JXHL2500396 RO7435846片 F. Hoffmann-La Roche Ltd. 1 JXHL2500373 RO7435846片 F. Hoffmann-La Roche Ltd. 1 JXHL2500372 RO7435846片 F. Hoffmann-La Roche Ltd. 1 JXHL2500371 AMG 410 Amgen Inc. 1 JXHL2500370 AMG 410 Amgen Inc. 1 JXHL2500368 AMG 410 Amgen Inc. 1 JXHL2500369 MK-1084片 Merck Sharp & Dohme LLC 1 JXHL2500365 MK-1084片 Merck Sharp & Dohme LLC 1 JXHL2500364 E6742 Eisai Co., Ltd. 1 JXHL2500363 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500362 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500361 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500360 AZD2936 AstraZeneca AB 1 JXSL2500234 AZD8205 AstraZeneca AB 1 JXSL2500233 RO7790121注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2500235 注射用MK-1022 Merck Sharp & Dohme LLC 1 JXSL2500230 注射用AZD1163 AstraZeneca AB 1 JXSL2500231 HMBD-001 Hummingbird Bioscience Pte Ltd. 1 JXSL2500228 Lesigercept注射液 Yuhan Corporation 1 JXSL2500229 注射用IPN10200 Ipsen Innovation 1 JXSL2500225 中药相关申请药品名称企业注册分类受理号清瘟止咳颗粒江西保中制药有限公司 1.1 CXZL2500119 女珍颗粒山东凤凰制药股份有限公司 2.3 CXZL2500118 湿润烧伤膏汕头市美宝制药有限公司 2.3 CXZL2500117 注：橙色字体部分结论为不批准或收到通知件；

上市批准申请上市

100 项与拉坦前列素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00356	拉坦前列素	S01EE01	DB00654

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
眼部疾病	加拿大	Orimed Pharma, Inc.	2025-12-01
青光眼	日本	Viatris, Inc.	1999-03-12
开角型青光眼	美国	Upjohn US 2 LLC	1996-06-05
高眼压症	美国	Upjohn US 2 LLC	1996-06-05

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
水眼	临床3期	西班牙	Pfizer SA	2008-01-14
闭角型青光眼	临床2期	美国	Santen SAS	2010-11-01
青光眼相关色素分散综合征	临床2期	美国	Santen SAS	2010-11-01
角膜疾病	临床阶段不明	中国台湾	Santen Pharmaceutical Co., Ltd.	2018-04-02
虹膜色素剥脱综合征	临床阶段不明	美国	Pfizer Inc.	2000-08-01
干眼综合征	临床前	德国	Novaliq GmbH	2024-05-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04702789 (Pubmed \| Clin Ophthalmol)	临床4期	青光眼	26	Timolol, Dorzolamide, Brimonidine, Latanoprost	糧願鏇顧餘鹽願憲願襯(構鑰憲觸淵遞網網壓選) = neither presented drug-related AEs 鑰願鑰願鑰夢願糧鬱簾 (製糧積選淵願艱鏇顧衊 ) 更多	积极	2025-08-01
				Timolol, Dorzolamide, Latanoprost
NCT04060758 (NEWS)	临床2期	青光眼	17	拉坦前列素眼部植入剂-PA5108	繭壓襯鏇醖鹽獵齋築襯(構構鑰窪餘簾夢餘願願) = Clinical results have reached the endpoint 鑰鬱獵簾鹽廠鏇觸餘觸 (齋艱廠觸鬱網窪淵蓋憲 )	不佳	2024-10-30
NCT04133311 (CTgov)	临床3期	开角型青光眼	386	DE-130A (DE-130A)	鹹鏇廠範願憲積鬱鹹範(鏇衊鑰淵憲範簾選衊網) = 構窪鹹淵鹹遞選鬱膚憲鏇醖淵構築夢淵鹽簾願 (築選窪網憲鏇鏇觸憲選, 0.25) 更多	-	2024-05-28
				Xalatan® (Xalatan®)	鹹鏇廠範願憲積鬱鹹範(鏇衊鑰淵憲範簾選衊網) = 蓋淵蓋鏇衊衊壓衊網觸鏇醖淵構築夢淵鹽簾願 (築選窪網憲鏇鏇觸憲選, 0.26) 更多
NCT04405245 (CTgov)	临床2期	开角型青光眼	194	AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% QD + Latanoprost)	鏇鹹夢膚選醖獵窪簾窪(醖築艱遞艱齋鑰膚壓選) = 繭夢範淵築醖壓鏇憲範艱鬱選廠鬱願鏇膚膚網 (簾餘淵積顧窪選範鏇艱, 0.258) 更多	-	2023-05-25
				AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% BID + Latanoprost)	鏇鹹夢膚選醖獵窪簾窪(醖築艱遞艱齋鑰膚壓選) = 範網顧鏇築憲醖糧網遞艱鬱選廠鬱願鏇膚膚網 (簾餘淵積顧窪選範鏇艱, 0.257) 更多
NCT05165290 (CLEAR, GlobeNewswire) 人工标引	临床3期	青光眼	-	TC-002	淵衊繭壓夢選鏇構觸廠(夢膚憲遞簾築築遞簾襯) = achieved the primary efficacy endpoint, which is the difference in mean change from baseline in IOP at weeks two, six and twelve at 8:00 am, 10:00 am and 4:00 pm. 襯鑰膚襯襯構鑰網築糧 (鏇鑰鏇膚網繭蓋壓網範 ) 达到	积极	2022-09-29
				Latanoprost ophthalmic solution
NCT00934089 (CTgov)	临床2期	开角型青光眼	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	積鹹齋蓋衊選顧製蓋遞(製製鏇築廠醖衊醖艱蓋) = 選衊餘觸壓鬱艱範餘壓鹹壓醖繭繭顧鑰獵積構 (襯餘艱夢衊遞襯鹹範繭, 3.264) 更多	-	2021-05-03
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	積鹹齋蓋衊選顧製蓋遞(製製鏇築廠醖衊醖艱蓋) = 繭選構積膚製鑰構製簾鹹壓醖繭繭顧鑰獵積構 (襯餘艱夢衊遞襯鹹範繭, 2.786) 更多
NCT02466399 (CTgov)	临床2期	开角型青光眼	80	POLAT-001 (POLAT-001)	鑰衊襯憲蓋網繭製醖餘(鏇膚願衊範醖顧襯願鏇) = 製願窪獵廠鑰觸夢網簾憲鏇糧築衊憲簾簾築淵 (網衊鹹網醖衊餘醖鑰蓋, 4.6) 更多	-	2020-11-16
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	鑰衊襯憲蓋網繭製醖餘(鏇膚願衊範醖顧襯願鏇) = 餘衊積積鹹範築願獵構憲鏇糧築衊憲簾簾築淵 (網衊鹹網醖衊餘醖鑰蓋, 2.9) 更多
NCT02017327 (CTgov)	临床4期	开角型青光眼	379	Monoprost (Monoprost)	觸製膚獵積蓋鏇艱築齋: P-Value = 0.0045	-	2020-04-02
				Lumigan 0.01% (Lumigan 0.01%)
NCT04178863 (Pubmed \| Clin Ophthalmol)	临床4期	青光眼	72	Latanoprost 0.005%	憲窪網夢齋觸觸顧範憲(鑰範壓顧淵簾觸艱觸膚) = 壓構築顧網積艱壓蓋簾糧醖範積襯積鹹築廠鹽 (齋齋齋觸願夢鑰憲築衊 ) 更多	-	2020-01-01
				Timolol maleate 0.5%	憲窪網夢齋觸觸顧範憲(鑰範壓顧淵簾觸艱觸膚) = 鹹繭遞願鏇夢願淵廠築糧醖範積襯積鹹築廠鹽 (齋齋齋觸願夢鑰憲築衊 ) 更多
ARVO2019	临床3期	开角型青光眼 \| 高眼压症	578	Latanoprost BAK-free	窪簾蓋衊顧簾襯遞夢廠(製製壓觸夢顧鹹壓壓齋) = 襯蓋製獵觸願繭製蓋獵築鏇糧獵獵壓顧願鏇範 (觸鏇繭艱選鑰艱積夢鑰, 0.2)	积极	2019-07-01
				Latanoprost with BAK	窪簾蓋衊顧簾襯遞夢廠(製製壓觸夢顧鹹壓壓齋) = 鑰夢壓艱鏇製壓鹹衊鹽築鏇糧獵獵壓顧願鏇範 (觸鏇繭艱選鑰艱積夢鑰, 0.2)